COPD临床试验中加重报告频率的国际差异
该研究分析了三项跨国随机试验中29,756例COPD患者的数据,比较不同国家报告的加重率差异。结果显示,不同国家间平均加重率存在2-3倍差异,且不受人口学特征、研究方案或入组时报告加重史的影响。各国在医疗定义的加重报告上存在持续差异,这解释了为何需要大型研究才能显示减少加重风险的治疗差异。
要点
- 不同国家COPD加重报告率存在2-3倍差异,与人口学特征和研究方案无关。
- 各国加重报告排序在多项试验中保持相对稳定,但重度加重排序不同。
- 跨国试验需考虑国家间加重报告差异对样本量和结果解释的影响。
核心结论
- 参与COPD试验的国家在医疗定义的加重报告上存在持续差异,这有助于解释为何需要大型研究才能显示减少加重风险的治疗差异。
研究设计与样本
- 回顾性分析三项大型多中心国际随机试验,共纳入41个国家29,756例患者,试验历时18年,比较支气管扩张剂和/或吸入糖皮质激素与单用支气管扩张剂和/或安慰剂。
主要发现
- 在至少参与两项试验且贡献30例以上患者的30个国家中,最高与最低三分位国家的平均加重率相差2-3倍。
- 这些差异不能用人口学特征、研究方案或入组时报告的加重史来解释。
- 在参与全部试验的18个国家中,加重史最高三分位和最低三分位各有一半国家在各项试验中保持原分组。
- 重度加重在国际间的排序不同。
关键数值与推荐
- 加重定义:使用抗生素和/或口服糖皮质激素为中度,需要住院为重度。
- 分析纳入41个国家29,756例患者,重点分析30个贡献30例以上且参与至少两项试验的国家。
临床怎么用
- 解读跨国COPD试验的加重终点时,应考虑国家间报告差异可能影响结果。
- 设计COPD加重相关研究时,需考虑国家间报告差异对样本量估算和结果解释的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Exacerbations of chronic obstructive pulmonary disease (COPD) are an important endpoint in multinational clinical treatment trials, but the observed event rate is often lower than anticipated and appears to vary between countries. Objectives: We investigated whether systematic differences in national exacerbation rates might explain this observed variation. Methods: We reviewed data from three large multicenter international randomized trials conducted over an 18-year period with different designs and clinical severities of COPD, comparing bronchodilator and/or inhaled corticosteroids with bronchodilators alone and/or placebo. Exacerbations were defined by antibiotic and/or oral corticosteroid use (moderate) or need for hospitalization (severe). We calculated crude exacerbation rates in the 30 countries contributing 30 or more patients to at least two trials. We grouped data by exacerbation rate based on their first study contribution. Measurements and Main Results: For the 29,756 patients in 41 countries analyzed, the mean exacerbation rate was two- to threefold different between the highest and lowest tertiles of the recruiting nations. These differences were not explained by demographic features, study protocol, or reported exacerbation history at enrollment. Of the 18 countries contributing to all trials, half of those in the highest and half in the lowest tertiles of exacerbation history remained in these groups across trials. Severe exacerbations showed a different rank order internationally. Conclusions: Countries contributing to COPD trials differ consistently in their reporting of healthcare-defined exacerbations. These differences help explain why large studies have been needed to show differences between treatments that decrease exacerbation risk.
引用
- Calverley PMA, Martinez FJ, Vestbo J, et al. International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. Am J Respir Crit Care Med. 2022. PMID: 35363593. doi:10.1164/rccm.202111-2630OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。